Reply to A. Oguz et al

J Clin Oncol. 2016 Feb 20;34(6):640-1. doi: 10.1200/JCO.2015.65.1034. Epub 2015 Dec 7.

Authors

Ciara C O'Sullivan¹, Eileen Holmes², Christine Campbell², Ian Bradbury², Jo Anne Zujewski³, Richard D Gelber⁴

Affiliations

¹ National Cancer Institute, National Institutes of Health, Bethesda, MD ciara.o'sullivan@nih.gov.
² Frontier Science, Inverness-shire, Scotland.
³ National Cancer Institute, National Institutes of Health, Bethesda, MD.
⁴ Harvard Medical School, Harvard T.H. Chan School of Public Health, Dana-Farber Cancer Institute, and Frontier Science and Technology Research Foundation, Boston, MA.

PMID: 26644531
DOI: 10.1200/JCO.2015.65.1034

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / enzymology*
Female
Humans
Receptor, ErbB-2 / biosynthesis*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Receptor, ErbB-2